Loading...
Loading...
In a report published Wednesday, Jefferies analyst Omotayo Okusanya upgraded the rating on
Sabra Health Care REITSBRA from Hold to Buy, but lowered the price target from $27.00 to $26.00.
In the report, Jefferies noted, “We had previously downgraded SBRA stock from Buy to Hold back in April on concerns of valuation following a 250% run-up in the stock since 2011. However, with the stock now down over 26% since May, shares appear oversold, offering an attractive entry point. While a rising cost of capital and recent lack of deal flow are concerns, recent pipeline agreements suggest new transactions are imminent. Upgrade to Buy but lower PT to $26.”
Sabra Health Care REIT closed on Tuesday at $22.49.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in